⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

March 26, 2024The Pediatric Infectious Disease JournalOpen Access

A Phase Three Study of the Safety and Immunogenicity of a Four-dose Series of 20-Valent Pneumococcal Conjugate Vaccine in Healthy Infants

View Full Paper

Ask AI

Bookmark

Share

Abstract

The 20-valent pneumococcal conjugate vaccine (PCV20) was developed to extend pneumococcal disease protection beyond 13-valent PCV (PCV13).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Senders et al. (2024) studied this question.

synapsesocial.com/papers/68e7242fb6db64358769db57 https://doi.org/10.1097/inf.0000000000004334

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1A Phase 3, Single-Arm Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine in Healthy Children 15 Months Through <18 Years of Age2024 · 7 citations
2Phase 3 Safety and Immunogenicity Study of a Three-dose Series of Twenty-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers2024 · 32 citations
3Safety of a 4-Dose 20-Valent Pneumococcal Conjugate Vaccine Series in Infants: A Randomized Trial2024 · 5 citations
4Safety and Immunogenicity of 20-valent Pneumococcal Conjugate Vaccine According to Number and Timing of Primary Series DosesLate-Phase Clinical Trial · 2026
5An overview of the clinical development of the 20-valent pneumococcal conjugate vaccine in adultsReview · 2026 · 1 citations